Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2015 Jul 21;24(10):1564–1573. doi: 10.1158/1055-9965.EPI-15-0021

Table 1.

Distribution of study subjects of the Harvard Lung Cancer Study, the CARET study, the Texas Lung Study, and the ICARE study by demographic and risk factors

Harvard Lung Cancer Study
CARETa
Texas Lung Study
ICAREb
Variable Case
(n=833)
Control
(n=739)
p-value Case
(n=394)
Control
(n=390)
p-value Case
(n=1154)
Control
(n=1137)
p-value Case
(n=1412)
Control
(n=1119)
p-value













Age (years)c 65.5 (10.2) 59.3 (11.5) <0.0001 70.3 (5.3) 71.6 (5.3) 0.03 62.1 (10.8) 62.1 (8.9) 0.013 59.6 (9.3) 58.1 (9.8) 0.0002
Sex 0.01 0.86 0.87 <0.0001
    Male (%) 396 (47.5) 397 (53.7) 252 (64.0) 247 (63.3) 658 (57.0) 644 (56.6) 1183 (83.8) 1011 (90.3)
    Female (%) 437 (52.5) 342 (46.3) 142 (36.0) 143 (36.7) 496 (43.0) 493 (43.4) 229 (18.2) 108 (9.7)
Smoking <0.0001 0.62 0.01 <0.0001
    Current smokingd 366 (43.9) 232 (31.4) 306 (77.7) 297 (76.2) 550 (47.7) 481 (42.3) 628 (44.5) 278 (24.8)
    Pack-yearsc 55 (33.9) 29.7 (26.5) <0.0001 53.1 (21.5) 52.0 (22.5) 0.85 51.5 (31.4) 44.6 (30.2) 38.9 (23) 18.9 (17.2) <0.0001
Asbestos Exposure 0.049 0.73 0.002 0.0019
    Never 650 (78.0) 606 (82.0) 333 (84.5) 333 (85.4) 990 (86.2) 1031 (90.8) 536 (38.0) 493 (44.1)
    Ever 183 (22.0) 133 (18.0) 61 (15.5) 57 (14.6) 159 (13.8) 105 (9.2) 876 (62.0) 626 (55.9)
    Asbestos Exposure
Scorece 0.6 (1.4) 0.5 (1.2) 0.016 0.5 (1.1) 0.4 (1.0) 0.3 NA NA 0.7 (1.1) 0.5 (0.9) <0.0001
Histology
    Adenocarcinoma 406 (48.7) 105 (26.7) 597 (51.7) 536 (38.0)
    Squamous 192 (23.1) 70 (17.8) 309 (26.8) 452 (32.0)
    Small cell carcinoma 85 (10.2) 52 (13.2) 0 (0.0) 208 (14.7)
    Other 150 (18.0) 167 (42.3) 248 (21.5) 216 (15.3)
a

CARET, Beta-Carotene and Retinol Efficacy Trial

b

ICARE, Investigation of occupational and environmental CAuses of REspiratory cancers

c

Mean(SD)

d

Current or quit within the last year

e

log-transformed